Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China

作者：Jieya Wu, Baoguo Sun, Li Hou, Fulan Guan, Liyuan Wang, Peikwen Cheng, Sophia B Scobell, Yung‐Chi Cheng, Wing Lam · 发表于：Frontiers in Pharmacology · 年份：2021 · DOI：10.3389/fphar.2020.615287 · 被引用次数：17 · 研究领域：Long-Term Effects of COVID-19、COVID-19 Clinical Research Studies、Acupuncture Treatment Research Studies

During the outbreak of the novel coronavirus disease (COVID-19), the Chinese government took a series of public health measures to tackle the outbreak and recommended six traditional Chinese medicine (TCM) evolved formulas, collectively referred to as "3-drugs-3-formulas", for the treatment. In this prospective article, we will discuss how these six formulas evolved from TCM and what their underlying mechanisms of actions may be by evaluating the historical usage of the component formulas, the potential targeted pathways for the individual herbs used by STAR (signal transduction activity response) database from our laboratory, and the pathogenesis of COVID-19. Five of the six recommended formulas are administered orally, while the sixth is taken as an injection. Five classic categories of herbs in the six formulas including "Qing-Re", "Qu-Shi", "Huo-Xue", "Bu-Yi" and "Xing-Qi" herbs are used based on different stages of disease. All five oral formulas build upon the core formula Maxingshigan Decoction (MD) which has anti-inflammatory and perhaps antiviral actions. While MD can have some desired effects, it may not be sufficient to treat COVID-19 on its own; consequently, complementary classic formulas and/or herbs have been added to potentiate each recommended formula's anti-inflammatory, and perhaps anti-renin-angiotensin system (RAS)-mediated bradykinin storm (RBS) and antiviral effects to address the unique medical needs for different stages of COVID-19. The key actions of...